Drug research

Brelovitug 300 mg

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as BJT-778; BTG

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330	MIRM	Phase 3	Active not recruiting	2026-08Estimated
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionNCT06907290	MIRM	Phase 2, Phase 3	Active not recruiting	2029-05Estimated
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908	MIRM	Phase 3	Recruiting	2027-06-30Estimated

MIRMActive not recruitingPrimary completion: 2026-08 · Estimated

Trial details

MIRMActive not recruitingPrimary completion: 2029-05 · Estimated

Trial details

MIRMRecruitingPrimary completion: 2027-06-30 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.